Bernhardt G. Zeiher

CIK: 0001971421

Transaction Breakdown

Open Market Buys (P)2 (25.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)6 (75.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (3)

TRDA

Entrada Therapeutics, Inc.

Director

AMLX

Amylyx Pharmaceuticals, Inc.

Director

ABEO

ABEONA THERAPEUTICS INC.

Director

Discretionary Trading P&L

Holdings

Transaction History (8 total)

TRDA
Entrada Therapeutics, Inc.
Jun 10, 2026
Award(A)
Stock Option (Right to Buy)
Direct
19K shares-
AMLX
Amylyx Pharmaceuticals, Inc.
Jun 4, 2026
Award(A)
Stock Option (right to buy)
Direct
24.4K shares-
TRDA
Entrada Therapeutics, Inc.
May 20, 2026
Purchase(P)
Indirect
5K shares at avg. $5.86$29K
ABEO
ABEONA THERAPEUTICS INC.
Jan 26, 2026
Award(A)
Direct
37.3K shares-
TRDA
Entrada Therapeutics, Inc.
Jun 11, 2025
Award(A)
Stock Option (Right to Buy)
Direct
19K shares-
AMLX
Amylyx Pharmaceuticals, Inc.
Jun 5, 2025
Award(A)
Stock Option (right to buy)
Direct
25K shares-
AMLX
Amylyx Pharmaceuticals, Inc.
Mar 20, 2025
Purchase(P)
Direct
10K shares at avg. $3.70$37K
ABEO
ABEONA THERAPEUTICS INC.
Jan 31, 2025
Award(A)
Direct
36.1K shares-

		Type	Shares	Price		Ownership
Jun 10, 2026	TRDA Entrada Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	19,000	-	-	Direct
Jun 4, 2026	AMLX Amylyx Pharmaceuticals, Inc.	Award(A) Stock Option (right to buy)	24,372	-	-	Direct
May 20, 2026	TRDA Entrada Therapeutics, Inc.	Purchase(P)	5,000	$5.86	$29,316	Indirect
Jan 26, 2026	ABEO ABEONA THERAPEUTICS INC.	Award(A)	37,313	-	$0	Direct
Jun 11, 2025	TRDA Entrada Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	19,000	-	-	Direct
Jun 5, 2025	AMLX Amylyx Pharmaceuticals, Inc.	Award(A) Stock Option (right to buy)	25,000	-	-	Direct
Mar 20, 2025	AMLX Amylyx Pharmaceuticals, Inc.	Purchase(P)	10,000	$3.70	$37,005	Direct
Jan 31, 2025	ABEO ABEONA THERAPEUTICS INC.	Award(A)	36,101	-	-	Direct

1-8 of 8 transactions

About Zeiher Bernhardt G

Zeiher Bernhardt G (SEC CIK 0001971421) files insider reports with the SEC as Director of Entrada Therapeutics, Inc. (TRDA), Director of Amylyx Pharmaceuticals, Inc. (AMLX) and Director of ABEONA THERAPEUTICS INC. (ABEO).

Signal8 holds 8 ownership filings by Zeiher Bernhardt G, all Form 4s, filed between Feb 3, 2025 and Jun 12, 2026. Those filings report 8 transactions, from Jan 31, 2025 to Jun 10, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Zeiher Bernhardt G's filings is in CAMBRIDGE, MA.

Recent filings by Zeiher Bernhardt G

Jun 10, 2026: Grant or award of TRDA derivative securities (Form 4, code A).
Jun 4, 2026: Grant or award of AMLX derivative securities (Form 4, code A).
May 20, 2026: Open-market purchase of TRDA shares (Form 4, code P).
Jan 26, 2026: Grant or award of ABEO shares (Form 4, code A).
Jun 11, 2025: Grant or award of TRDA derivative securities (Form 4, code A).

Other insiders filing for Entrada Therapeutics, Inc. (TRDA)

MPM BIOVENTURES 2018, L.P., 10% Owner
MPM BioVentures 2014, L.P., 10% Owner
Doshi Dipal, CEO
Dowden Nathan J, President & COO
Sethuraman Natarajan, President, Research & Develop.
WENTWORTH KORY JAMES, Chief Financial Officer

How to read Form 4 transaction codes